Centrum 7/6  banner

Timothy Walbert

Horizon adds gout drug with Crealta acquisition

Horizon adds gout drug with Crealta acquisition

DUBLIN, Ireland — Horizon Pharma plc plans to acquire Crealta Holdings LLC for $510 million in cash. Horizon said the deal will bring the company Krystexxa (pegloticase), the first and only Food and Drug Administration-approved drug for chronic refractory gout. “The Crealta acquisition further diversifies our portfolio of medicines and aligns with our focus of acquiring value-enhancing, clinically differentiated, long-life medicines

PP_1170x120_10-25-21